99mTc-Oncardia is the first 99mTc-sugar analogue cancer imaging agent specifically developed for use with SPECT cameras found in over 90% of the world’s hospitals. Prior to Oncardia the only way to image cancer was with FDG on PET cameras which are expensive and in less than 2% of the world’s hospitals. Cell>Point is completing a Phase 3 lung cancer imaging trial for Oncardia under an FDA approved Special Protocol Assessment (SPA). Oncardia offers many advantages over FDG PET imaging including access, cost, and the ability to monitor therapy.
Past and Current Clinical Trial Sites:
University of British Columbia The University of Texas M.D. Anderson Cancer Center
University of Chicago Medical Center Johns Hopkins Hospital
Mayo Clinic Decatur Memorial Hospital
Montefiore Medical Center Baptist Health
St. Louis University Medical Center John Cochran VA Medical Center